Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
IRVINE, Calif., May 27, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD). Investors who purchased or otherwise acquired shares between July 7, 2016 and April 9, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 19, 2017 lead plaintiff motion deadline.
If you purchased TherapeuticsMD shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food & Drug Administration identified deficiencies in its NDA for TX-004HR. When this news was announced, TherapeuticsMD’s stock price fell materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
